Timolol eyedrop-induced severe bronchospasm

Area of Science:

• Ophthalmology
• Pulmonology
• Pharmacology

Background:

• Glaucoma simplex and chronic obstructive pulmonary disease (COPD) are common conditions.
• Non-selective beta-adrenergic blocking agents like timolol are used to treat glaucoma.
• Systemic absorption of ophthalmic medications can lead to adverse effects.

Observation:

• A patient with glaucoma and COPD experienced daily asthma attacks after 1.5 years of timolol eyedrop use.
• A provocation test showed a 56% reduction in forced expiratory volume and induced bradycardia after timolol administration.
• Systemic side-effects may be linked to hepatic first-pass metabolism and rapid corneal absorption.

Findings:

• Timolol ophthalmic solution can trigger severe respiratory distress in patients with underlying pulmonary disease.
• The non-selective beta-blocker activity of timolol affects respiratory function.
• Ocular administration of timolol carries a risk of significant systemic adverse events.

Implications:

• Glaucoma patients with COPD require careful monitoring when initiating timolol eyedrops.
• Consider alternative glaucoma treatments or cautious use of beta-blockers in patients with respiratory conditions.
• Further research into safer glaucoma medications for patients with comorbid pulmonary disease is warranted.